Nuwellis, Inc. · NASDAQ:NUWE
Nuwellis — Investor Presentation (September 2021)
19 slides from Nuwellis's investor presentation, Sep 9, 2021
Slide 1: September 2021 Investor Presentation
S e p t e m b e r 2 0 2 1 FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2021 Nuwellis, Inc. 1
Slide 2: Forward Looking Statement
Forward Looking StatementThis presentation contains forward‐looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act, as amended regarding our plans, expectations, beliefs, estimates, goals and outlook for the f
Slide 3: Risk Factors
Risk Factors Investing in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all of the other information contained in our SEC filings. If any of the following risks actually occurs, our business, financial condition, resu
Slide 4: Dedicated to transforming the lives of patients suffering from fluid overload
is dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2021 Nuwellis, Inc. 44
Slide 5: Fluid Overload is a condition where there is too much fluid in the bloodstream
Fluid Overload is a condition where there is too much fluid in the bloodstream, vital organs and interstitial space Fluid overload is the leading cause of death for critically ill patients in the ICU within 90 days3In pediatric patients, fluid overload is associatedwith significant increases in mort
Slide 6: Diuretics: Standard of care with significant limitations
Diuretics:Standard of care with significant limitations >40% of heart failure patients have poor diureticresponse1High risk of rehospitalization2Long-term use of diuretics has been associated with kidney damage2-5Diuretics provide insufficient symptom relief and are associated with worsening heart f
Slide 7: A superior solution for fluid overload
7 SIMPLE FLEXIBLE SMARTFOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2021 Nuwellis, Inc. Safe and easy to use and flexible in applicationPredictably removes excess fluidNo significant changes to kidney function1Stabilizes or improves cardiac hemodynamics2-5Compared to diuretics, reduces hos
Slide 8: Key Milestones – Solid Progress
Key Milestones – Solid Progress FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2021 Nuwellis, Inc. 8 K E Y M I L E S T O N E S E X P E C T E D T I M I N G FDA 510(k) clearance of: Expanded use in pediatric population (≥ 20kg)Next generation Aquadex SmartFlow® console Complete Nationwide Acce
Slide 9: Treating the most vulnerable
$900M Market H E A R TF A I L U R E $150M Market P E D I A T R I C $950M Market C R I T I C A L C A R E TREATING THE MOST VULNERABLEFrom children1 to the elderly, our therapy is critical to improving care and outcomes FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2021 Nuwellis, Inc. 9 $2B 1
Slide 10: Providing Pediatric Patients with High Mortality Risk an Opportunity at Life
Providing Pediatric Patients with High Mortality Risk an Opportunity at Life (1) Attributes Group 1: <10kg Group 2: 10-20kg Group 3: >20kg # of Patients N=72 N=13 N=34 Primary disease 43% kidney29% cardiac 54% kidney31% other 38% kidney28% cardiac Survival at end oftreatment (Aquadex) 43 (60%) 13 (1
Slide 11: Growing Pediatric Business
Growing Pediatric BusinessIn five quarters, we have more than doubled the number of active and pipeline pediatric accounts Q1 2020 Q2 2021 10 24 29 45 34 74 # o f P e d i a t r i c A c c o u n t s > 100%increase in # of accts Active Pipeline Received 510(k) 11FOR INVESTOR PURPOSES ONLY: NOT FOR PROD
Slide 12: Aquadex SmartFlow removes excess fluid post cardiac surgery
Aquadex SmartFlow® simply & predictablyremoves excess fluid post cardiac surgery Additional fluid added to compensate for blood flowing through heart lung machine1 Immediately removing fluid post-surgeryReduces time to beextubated 2,3Shortens time in post op care and ICU length of stay3,4Improves ou
Slide 13: Fluid Overload is associated with greater mortality
Fluid Overload is associatedwith greater mortality1 90 - d a y m o r t a l i t y b yi n t r a v e n o u s f l u i d m e d i a n1.000Survival rates with No Excess Fluid0.975 0.950 0.925 0.900 Survival rates with Excess Fluid IVF <= Median IVF > Median0 10 20 30 40 50 60 70 80 90Survival (days) Excess
Slide 14: 10-Year Real-World Experience with Ultrafiltration
HF HOSPITALIZATIONS 10-Year Real-World Experiencewith Ultrafiltration1 A B I N G TO N H O S P I TA LJ E F F E R S O N H E A LT HRetrospective, single center analysis335 consecutive acutely decompensated heart failure patientsTreated with adjustable-rate UF using AquadexFluid removed weight lossUncha
Slide 15: Hospitals, Nuwellis and Patients: outpatient setting benefits
HospitalsHospitals actively trying to reduce economic burden of heart failure (HF)Reduced patient readmissions within 30- days may help decrease costly CMS penalties9Early intervention may help decrease patient hospital length of stay (LOS)5o Most US hospitals lose money on HF admissions: average LO
Slide 16: Financial Metrics: Quarterly Revenue
Financial Metrics Quarterly Revenue$ in 000s 2 0 2 1 g r o w t h c o n s i d e r a t i o n sExpand into new pediatric accountsIncrease utilization among existing pediatric accountsIncrease utilization to treat non-COVID 19 critically illpatients in ICUMaturing sales organization, strategy and struct
Slide 17: Investment Highlights
FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2021 Nuwellis, Inc. 17 Investment Highlights Attractive capital equipment + consumables revenue growth model$2 billion addressable market: pediatrics, critical care and heart failureLeveraging commercial infrastructure to rapidly penetrate pedia
Slide 18: Capitalization Table
Capitalization Table Common Shares Outstanding (Nasdaq: NUWE) 6,532,018 Series F Convertible Preferred (1) 23,114 Warrants from 2020 Financings (2) 1,479,040 Other warrants (3) 152,766 Options 812,561 Fully Diluted Shares 8,999,499 NO D E B T C A S H$24.0 million (as of June 30, 2021) C a p i t a l
Slide 19: Thank You
Thank You FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2021 Nuwellis, Inc. 19